12 questions with: Gerwin Winter
Gerwin Winter joined BeiGene in March 2021 as senior vice president, head of Europe. Driven by a passion to unlock patient access to the best care, Gerwin is responsible for building and leading the team in Europe that will bring BeiGene’s innovative medicines to patients across the continent. With a master’s degree in pharmacy from the University of Munich, Gerwin has worked in the pharmaceutical industry for nearly three decades, with a strong focus on haematology and oncology.
What are the main responsibilities of your current role?
BeiGene is a global biotechnology company with a mission to ensure that the most impactful medicines are available to the greatest number of people facing cancer and life-threatening diseases. Fundamentally, my responsibility is to uphold this mission in Europe by building on our commitment to grow in the region.
Our European story so far is in its early stages, but with over 400 employees currently based here, and our regional team doubling in 2022, our expansion plans are already going from strength to strength. We have been able to draw from the best science, talent, and collaborations – wherever they exist – through a combination of key offices in Europe, including our Hub in Switzerland, and remote employees based across the continent. Continuing and building on this legacy is my primary goal.
• Read the full article in pharmaphorum's Deep Dive digital magazine
